Drug intelligence / Profile preview

QLS31903

Development stage: Phase 1
Lead developer: Qilu Pharmaceutical
Modality: Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous (injection)

Overview

QLS31903 is an investigational antibody therapy developed by Qilu Pharmaceutical for the treatment of advanced solid tumors. It is currently in Phase 1 clinical trials, where it is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with advanced solid tumors. The trial includes a cohort specifically for patients whose tumors are positive for glypican-3 (GPC3), suggesting that GPC3 may be a target of this antibody. The drug is administered via injection (subcutaneous route). As of now, the precise mechanism of action has not been publicly disclosed[1][7][9].

Other names: QLS31903QLS-31903QLS 31903

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on QLS31903.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS31903.

Explore the full profile